PRISM BioLab Co

PRISM BioLab Co Financial Debt Ratio

Financial Debt Ratio of PRISM BioLab Co (206A.T) as of Oct 18, 2026.

Financial Debt Ratio

-

Last updated:

Financial Debt Ratio of PRISM BioLab Co is 2026 - . Financial Debt Ratio of PRISM BioLab Co was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd, headquartered in Fujisawa-shi, Kanagawa-ken, Japan, operates in the Pharmaceuticals sector within the Health Care industry. The company employs 17 full-time staff and is listed on 2 July 2024. PRISM BioLab focuses on drug discovery, utilizing its proprietary PepMetics technology to develop new pharmaceuticals. It operates through two business models: in-house development of drug discovery programs and joint development collaborations with pharmaceutical companies to target specific drug discovery opportunities. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

On Eulerpool you can find the complete historical development of Financial Debt Ratio PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co